Lampalizumab
Modify Date: 2024-01-21 21:20:39
Lampalizumab structure
|
Common Name | Lampalizumab | ||
|---|---|---|---|---|
| CAS Number | 1278466-20-8 | Molecular Weight | 46.96 (kDa) | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of LampalizumabLampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research[1][2]. |
| Name | Lampalizumab |
|---|
| Description | Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research[1][2]. |
|---|---|
| Related Catalog | |
| Target |
Factor D[1] |
| In Vivo | Lampalizumab 经静脉注射给食蟹猴后，5小时内血清因子D水平增加近10倍，有效中和了其抑制活性[1]。 |
| References |
| Molecular Weight | 46.96 (kDa) |
|---|